Biotech: Page 9
-
Medicare named the first 10 drugs up for negotiation. Now what?
The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.
By Karissa Waddick • Aug. 30, 2023 -
Q&A // Biotech Spotlight
‘We need to do better:’ A biotech CEO on standing apart from the crowd
The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.
By Michael Gibney • Aug. 29, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’
FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages.
By Karissa Waddick • Aug. 25, 2023 -
‘Eris’ and other new COVID strains accelerate vaccine push from Pfizer, Moderna, Novavax
New variants drive a need for another round of shots, and biopharma companies are stepping up to the plate.
By Michael Gibney • Aug. 24, 2023 -
Henrietta Lacks’ immortal cells put biopharma profits under a microscope
The HeLa cell line’s contributions to medical science were obtained without permission, and now biotechs profiting from its use are answering for it.
By Michael Gibney • Aug. 23, 2023 -
Biotech Spotlight
Brii Biosciences aims to come up big where Sage and Biogen fell short
The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.
By Kelly Bilodeau • Aug. 21, 2023 -
Behind Flagship Pioneering’s triumphs and tribulations
From the rise of Moderna to the fall of Kaleido, here's a look at the VC fund's biggest successes and failures to date.
By Karissa Waddick • Aug. 18, 2023 -
Pharma’s rare disease rush
Biogen’s acquisition of Reata Pharmaceuticals is the latest in a string of high-dollar rare disease deals over the last few months. What does it mean for industry?
By Meagan Parrish , Karissa Waddick • Aug. 14, 2023 -
Q&A // Biotech Spotlight
Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine
The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.
By Kelly Bilodeau • Aug. 14, 2023 -
Q&A
5 minutes with — Lundbeck CEO Dr. Deborah Dunsire
The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.
By Meagan Parrish • Aug. 11, 2023 -
Biogen’s Reata acquisition reflects biopharma’s inevitable M&A, IPO return to growth
July’s announcement from the beleaguered drugmaker signals the kind of shift the industry could see more of as M&A and IPOs tick up once again.
By Michael Gibney • Aug. 10, 2023 -
Podcast
Woman of the Week: AmyriAD Therapeutics’ Sharon Rogers
The CEO of the Alzheimer’s-focused biotech discusses its phase 3-ready candidate and what it could contribute to the bustling field.
By Taren Grom and Meagan Parrish • Aug. 9, 2023 -
Q&A // Biotech Spotlight
Why AbbVie’s former president has high hopes for this Flagship-backed biotech
The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.
By Karissa Waddick • Aug. 7, 2023 -
Pharma’s rocky love affair with oxytocin
Although research on using oxytocin as a drug has varied, Tonix Pharmaceuticals is banking on the “love hormone” to treat migraines, anxiety and more.
By Kelly Bilodeau • Aug. 7, 2023 -
Sponsored by Bio-Rad
A pioneering approach to biotherapeutic antibody discovery
Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous.
By Kimberley Bryon-Dodd, PhD • Aug. 7, 2023 -
New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine
A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.
By Michael Gibney • Aug. 3, 2023 -
Is the COVID-19 market crashing?
Pfizer’s recent earnings report could foretell major trouble in the market for pandemic products.
By Meagan Parrish • Aug. 3, 2023 -
Q&A // Biotech Spotlight
How CymaBay overcame a NASH failure for another shot at liver disease success
The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.
By Michael Gibney • Aug. 2, 2023 -
Biosimilar makers split strategies in bid to take on top-selling Humira
In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.
By Jonathan Gardner • July 26, 2023 -
Biogen’s layoffs are the latest in an industrywide slip
Over 100 biotech companies so far this year have cut staff due to persistent funding challenges.
By Karissa Waddick • July 26, 2023 -
Q&A
In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets
Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.
By Alexandra Pecci • July 25, 2023 -
Q&A
Google for genes? This AI company aims to curate the entire human genome.
Genomenon’s acquisition of their contract scientific partner Boston Genetics will help them unlock the potential of genetic knowledge.
By Michael Gibney • July 20, 2023 -
Q&A
A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here
Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.
By Taren Grom and Meagan Parrish • July 20, 2023 -
AI’s great expectations
With AI expectations riding high, here’s a look at some areas where the technology could be most useful in drug development.
By Karissa Waddick • July 19, 2023 -
Q&A
As biologics boom, here’s how manufacturers are keeping up
Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.
By Michael Gibney • July 19, 2023